Yousif Capital Management LLC Boosts Stake in Myriad Genetics, Inc. (NASDAQ:MYGN)

Yousif Capital Management LLC lifted its holdings in Myriad Genetics, Inc. (NASDAQ:MYGN) by 7.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,096 shares of the company’s stock after purchasing an additional 3,195 shares during the period. Yousif Capital Management LLC’s holdings in Myriad Genetics were worth $844,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. increased its position in shares of Myriad Genetics by 96.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 2,101 shares of the company’s stock valued at $34,000 after buying an additional 1,032 shares in the last quarter. Blue Trust Inc. grew its stake in Myriad Genetics by 21.4% in the 4th quarter. Blue Trust Inc. now owns 6,729 shares of the company’s stock valued at $129,000 after acquiring an additional 1,186 shares during the period. Clarus Wealth Advisors acquired a new stake in Myriad Genetics in the 4th quarter valued at $204,000. Mutual of America Capital Management LLC increased its holdings in Myriad Genetics by 8.1% in the 4th quarter. Mutual of America Capital Management LLC now owns 15,519 shares of the company’s stock worth $297,000 after acquiring an additional 1,167 shares in the last quarter. Finally, Inspire Investing LLC raised its position in Myriad Genetics by 40.8% during the third quarter. Inspire Investing LLC now owns 19,002 shares of the company’s stock worth $305,000 after acquiring an additional 5,505 shares during the period. Institutional investors and hedge funds own 99.02% of the company’s stock.

Myriad Genetics Trading Up 1.3 %

Shares of NASDAQ MYGN opened at $19.47 on Friday. The company has a quick ratio of 1.87, a current ratio of 2.01 and a debt-to-equity ratio of 0.05. The company has a 50-day moving average of $20.73 and a 200 day moving average of $19.77. Myriad Genetics, Inc. has a 12-month low of $13.82 and a 12-month high of $24.21.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings data on Tuesday, February 27th. The company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. The firm had revenue of $196.60 million for the quarter, compared to the consensus estimate of $194.80 million. Myriad Genetics had a negative return on equity of 8.03% and a negative net margin of 34.96%. The firm’s revenue was up 10.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.20) earnings per share. On average, sell-side analysts expect that Myriad Genetics, Inc. will post -0.36 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group boosted their target price on shares of Myriad Genetics from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Monday, January 29th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $23.17.

About Myriad Genetics

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.